Canntab Therapeutics Limited
CTABF · OTC
2/28/2023 | 11/30/2022 | 8/31/2022 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.06 | -0.01 |
| FCF Yield | -5.08% | -6.67% | -7.12% | -8.05% |
| EV / EBITDA | -16.77 | -4.89 | -80.00 | -10.52 |
| Quality | ||||
| ROIC | 131.16% | -150.52% | -61.51% | -64.27% |
| Gross Margin | 22.16% | 2.39% | 68.79% | -137.42% |
| Cash Conversion Ratio | 0.09 | 0.06 | 1.13 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | -55.67% | -27.49% | 667,360.50% | 30.06% |
| Free Cash Flow Growth | 41.95% | 86.77% | 33.49% | -1.54% |
| Safety | ||||
| Net Debt / EBITDA | -11.77 | -3.20 | -15.50 | -1.10 |
| Interest Coverage | -2.14 | -3.08 | -3.56 | -5.45 |
| Efficiency | ||||
| Inventory Turnover | -0.06 | 0.04 | 0.02 | 0.19 |
| Cash Conversion Cycle | -446.41 | 1,636.00 | 3,447.15 | 792.14 |